Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Darzalex. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Daratumumab (sold as Darzalex), first approved Nov 16, 2015, with 14 new uses approved and 0 published complete response letters.
First approved: Nov 16, 2015
Applications: 1
New uses approved: 14
Complete response letters: 0
Medicare spending, 2025: $133M
First approved in the EU: May 20, 2016
First approved in Japan: Sep 27, 2017
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 22 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
DarzalexDrugs with a new dosage indicated for the treatment of multiple myeloma. · Janssen Pharmaceutical K.K. · Nov 27, 2020
DarzalexDrugs with a new dosage indicated for the treatment of multiple myeloma. · Janssen Pharmaceutical K.K. · Dec 20, 2019
DarzalexDrugs with a new indication and a new dosage for the treatment of multiple myeloma. · Janssen Pharmaceutical K.K. · Aug 22, 2019 · Review report
Darzalex, new ingredientDrugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. · Janssen Pharmaceutical K.K. · Sep 27, 2017 · Review report
Clinical Trials
233 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA